- Home
- ARMN vs XERS Comparison
ARMN vs XERS Comparison
Compare ARMN & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMN
- XERS
- Stock Information
- Founded
- ARMN 1992
- XERS 2005
- Country
- ARMN Canada
- XERS United States
- Employees
- ARMN N/A
- XERS N/A
- Industry
- ARMN
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- ARMN
- XERS Health Care
- Exchange
- ARMN Nasdaq
- XERS Nasdaq
- Market Cap
- ARMN 1.4B
- XERS 1.3B
- IPO Year
- ARMN N/A
- XERS 2018
- Fundamental
- Price
- ARMN $9.17
- XERS $8.30
- Analyst Decision
- ARMN Strong Buy
- XERS Strong Buy
- Analyst Count
- ARMN 1
- XERS 7
- Target Price
- ARMN $17.00
- XERS $8.00
- AVG Volume (30 Days)
- ARMN 1.9M
- XERS 1.8M
- Earning Date
- ARMN 11-11-2025
- XERS 11-07-2025
- Dividend Yield
- ARMN N/A
- XERS N/A
- EPS Growth
- ARMN N/A
- XERS N/A
- EPS
- ARMN 0.02
- XERS N/A
- Revenue
- ARMN $646,783,000.00
- XERS $246,025,000.00
- Revenue This Year
- ARMN $49.45
- XERS $43.89
- Revenue Next Year
- ARMN $11.08
- XERS $20.40
- P/E Ratio
- ARMN $379.75
- XERS N/A
- Revenue Growth
- ARMN 38.72
- XERS 35.62
- 52 Week Low
- ARMN $3.29
- XERS $2.69
- 52 Week High
- ARMN $9.95
- XERS $8.32
- Technical
- Relative Strength Index (RSI)
- ARMN 60.63
- XERS 70.73
- Support Level
- ARMN $9.17
- XERS $7.29
- Resistance Level
- ARMN $9.95
- XERS $7.89
- Average True Range (ATR)
- ARMN 0.36
- XERS 0.27
- MACD
- ARMN -0.00
- XERS -0.07
- Stochastic Oscillator
- ARMN 57.84
- XERS 96.65
About ARMN Aris Mining Corporation
Aris Mining Corp is engaged in the acquisition, exploration, development, and operation of gold properties in Colombia, Guyana, and Canada. It owns and operates its Segovia Operations, Soto Norte Project and Marmato Mine in Colombia, the Toroparu Project in Guyana, and the Juby Project in Ontario, Canada. The company generates revenue from the sale of gold and silver.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).